SLGLのチャート
SLGLの企業情報
| symbol | SLGL |
|---|---|
| 会社名 | Sol-Gel Technologies Ltd （ソル・ゲル・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins sirs-t and vered. The Company is designed its proprietary silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert inorganic silica shell which creates an unnoticeable barrier between the active ingredient and the skin. ソル・ゲル・テクノロジ―ズはイスラエルの製薬企業。独自のマイクロカプセル化技術プラットフォ―ムに基づき、皮膚用医薬品の開発と製品化を行う。臨床試験第2段階を完了した主力製品候補には、膿ほう性ロザケア(酒さ)の治療薬VEREDや、尋常性挫創の治療薬TWINおよびSIRS-Tがある。同社はまた、その他の皮膚用ジェネリック医薬品の開発も手掛ける。 Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications. |
| 本社所在地 | Weizmann Science Park 7 Golda Meir Street Ness Ziona 7403650 ISR |
| 代表者氏名 | Alon Seri-Levy アロン・セリ・レヴィ |
| 代表者役職名 | Chief Executive Officer Co-Founder Director |
| 電話番号 | +972 8-931-3433 |
| 設立年月日 | 35704 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.sol-gel.com |
| nasdaq_url | https://www.nasdaq.com/symbol/slgl |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -32.72400 |
| 終値（lastsale） | 7.2 |
| 時価総額（marketcap） | 136439769.6 |
| 時価総額 | 時価総額（百万ドル） 115.21580 |
| 売上高 | 売上高（百万ドル） 0.08100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） ー |
| 当期純利益 | 当期純利益（百万ドル） -32.35600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sol Gel Technologies Ltd revenues decreased from $0K to -$93K. Net loss increased 7% to $12.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development Expense increase of 12% to $10.5M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 8% to $2.7M (expense). |
SLGLのテクニカル分析
SLGLのニュース
7 Biotech Stocks That Could Be the Next Big Thing 2023/03/15 15:44:07 InvestorPlace
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent relevance. No matter what’s going on with the economy or which bank happens to be failing, scientists will continue marching forward. Chronic diseases don’t wait for economic cycles to pass by and neither does the medical innovation sector. Indeed, when the equities sector crumbled in 2022, the broader healthcare sector generally provided a solid performance . While individual biotechs present volatility risks, the search for viable therapeutics represents a perpetual endeavor. On that note, below are the biotech stocks to add to your portfolio.
Sol-Gel Technologies GAAP EPS of -$0.65 misses by $0.15, revenue of $3.88M misses by $1.8M 2023/03/10 12:39:20 Seeking Alpha
Sol-Gel Technologies press release (SLGL): FY GAAP EPS of -$0.65 misses by $0.15.Revenue of $3.88M (-87.6% Y/Y) misses by $1.8M.As of December 31,…
Sol-Gel Technologies GAAP EPS of -$0.15 misses by $0.08, revenue of $0.3M misses by $3.15M 2022/11/10 09:41:55 Seeking Alpha
Sol-Gel Technologies press release (SLGL): Q3 GAAP EPS of -$0.15 misses by $0.08.Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M.As of September 30, 2022, Sol-Gel had $25.5 million…
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/10 09:00:00 GlobeNewswire
NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge 2022/10/24 16:23:48 Benzinga
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.
Sol-Gel Technologies GAAP EPS of -$0.15 misses by $0.08, revenue of $0.3M misses by $3.15M 2022/11/10 09:41:55 Seeking Alpha
Sol-Gel Technologies press release (SLGL): Q3 GAAP EPS of -$0.15 misses by $0.08.Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M.As of September 30, 2022, Sol-Gel had $25.5 million…
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/10 09:00:00 GlobeNewswire
NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge 2022/10/24 16:23:48 Benzinga
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.
Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M 2022/08/04 13:10:30 Seeking Alpha
Sol-Gel Technologies press release (SLGL): Q2 GAAP EPS of $0.01 beats by $0.11.Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M.
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update 2022/08/04 10:00:00 GlobeNewswire
NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge 2022/10/24 16:23:48 Benzinga
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. The Dow traded up 1.03% to 31,402.66 while the NASDAQ rose 0.07% to 10,867.39. The S&P 500 also rose, gaining, 0.66% to 3,777.37. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 1.7% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and Sol-Gel Technologies Ltd. (NASDAQ: SLGL ). In trading on Monday, consumer discretionary shares fell by 0.8%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shares shot up 70% to $35.03 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.
Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M 2022/08/04 13:10:30 Seeking Alpha
Sol-Gel Technologies press release (SLGL): Q2 GAAP EPS of $0.01 beats by $0.11.Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M.
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update 2022/08/04 10:00:00 GlobeNewswire
NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Citigroup, Bank of America And 48 Stocks Moving In Friday''s Mid-Day Session 2022/07/15 16:11:01 Benzinga
Gainers United Maritime Corporation (NASDAQ: USEA ) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday. Cemtrex, Inc. (NASDAQ: CETX ) gained 52.8% to $0.4759 after gaining over 5% on Thursday. Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) rose 43.5% to $0.3101 after declining over 36% on Thursday. NYMOX received deficiency letter from NASDAQ. ITHAX Acquisition Corp. (NASDAQ: ITHX ) surged 34.7% to $13.41. NexImmune, Inc. (NASDAQ: NEXI ) jumped 29.9% to $1.9099 after the company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.. ToughBuilt Industries, Inc. (NASDAQ: TBLT ) gained 21% to $2.8899 after gaining 10% on Thursday. ToughBuilt Industries recently announced its Q2 gross sales through Amazon were $3.56 million, representing a 20% year-over-year increase. Greenbrook TMS Inc. (NASDAQ: GBNH ) rose 19.7% to $1.6999.
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference 2022/06/01 12:00:00 GlobeNewswire
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that Chief Executive Officer, Alon Seri-Levy, will present a corporate update at the 2022 Jefferies Global Healthcare Conference to be held June 8 -10, 2022 in-person, in New York, NY.